免疫測定法市場：製品、技術、検体、適応症、エンドユーザー別-2024-2030年の世界予測

免疫測定法市場規模は、2023年に263億米ドルと推計され、2024年には282億9,000万米ドルに達し、CAGR 7.24%で2030年には429億米ドルに達すると予測されています。

免疫測定法は、タンパク質、ホルモン、抗体、その他の生物学的関連物質を含む幅広い分子の定量や検出に使用される、高感度で特異的な生化学技術です。免疫測定法市場の成長は、慢性疾患の有病率の増加、個別化医療に対する需要の高まり、腫瘍診断における免疫測定法の使用拡大、精度の向上と高いスループット性能につながる技術の進歩など、いくつかの影響要因に起因しています。さらに、COVID-19のパンデミックも、迅速検査ソリューションに対する需要の急増により、この市場の成長に大きく寄与しています。しかし、高度な免疫測定法システムに関連する高コストは、小規模検査室や資源が限られた環境での採用を妨げる可能性があります。さらに、製品承認に関する厳しい規制ガイドラインは、新製品の市場投入までの時間を長引かせる可能性があります。このような課題を克服し、免疫測定法市場におけるビジネスの成長を維持するために、企業は、世界中のさまざまなヘルスケア環境において、より幅広いユーザー層に対応する費用対効果の高いソリューションを生み出すための研究開発に注力するなど、技術革新と研究の可能性を模索しています。さらに、学術機関や研究センターと協力して、アッセイ設計における画期的なイノベーションを促進し、新規分析対象物や既存製品では現在対応していないアプリケーションをターゲットとしています。これらとともに、市場参入企業は疾病の早期発見のための新規バイオマーカーを開発しており、免疫測定法の臨床応用の拡大につながっています。

製品感染症や自己免疫疾患の診断のための新規免疫測定法キットの開発

免疫測定法の中核をなす分析装置は、検体中の標的分析物の検出と測定を容易にします。これらの分析装置は、臨床検査室、病院、製薬会社、研究機関などで、様々なバイオマーカーのスクリーニングや、ホルモン、タンパク質、病原体などの特定分析物の検出に使用されています。そのため、迅速なTAT（Turnaround Time）、高スループット、使いやすいインターフェースを備えた分析装置へのニーズが高まっています。このようなニーズに応えるため、各メーカーは化学発光ベースの検出システム、マルチプレックス・アッセイ、高度なソフトウェア・ソリューションなどの革新的な技術を導入し、効率の向上と正確な結果の提供に努めています。

消耗品は、高品質の試薬、キット、その他の使い捨て可能なアイテムを通じて信頼性の高い検査結果を保証することにより、免疫測定法において重要な役割を果たしています。消耗品の中で、試薬は抗体と抗原の特異的な結合相互作用を促進することにより、免疫測定法の実施に不可欠な役割を果たします。試薬には、一次抗体、二次抗体、酵素標識コンジュゲート、基質、緩衝液、その他必要な化学薬品が含まれます。これらの試薬の性能特性は、アッセイの信頼性と再現性に直接影響します。免疫測定法キットは、特定のアッセイを実施するための詳細なプロトコールとともに、あらかじめパッケージ化された試薬一式で構成されています。使いやすさ、標準化、最適化された性能などの利点により、世界中のラボですぐに使えるキットの需要が高まっています。マイクロウェルプレートとチューブは、様々な免疫測定法の支持構造として機能し、複数のサンプルを同時に分析することを可能にすることで、スケーラビリティとハイスループット機能を提供します。その材料組成は、分析物の検出に最適な条件を維持しながら、非特異的結合を最小限に抑える上で重要な役割を果たしています。

技術食物アレルギーや乱用薬物治療への酵素結合免疫吸着測定技術の活用

化学発光免疫測定法（CLIA）は、化学反応による発光を通じて分析対象物の濃度を測定する高感度かつ特異的な技術です。CLIAは、その高いスループット、迅速な結果、良好なS/N比により、低存在量のバイオマーカー、感染症、ホルモンレベルの検出に有益であるため、最近人気を博しています。酵素結合蛍光アッセイ（ELFA）は、酵素標識抗体と蛍光基質を用いて特定の分析物を定量します。ELFAは、比較的少量のサンプルで高い感度と特異性を持つ迅速な分析を提供します。この技術は、感染症診断、自己免疫疾患検出、治療薬モニタリングなど、様々なアプリケーションで有用です。酵素結合免疫吸着測定法（ELISA）は、タンパク質、ペプチド、ホルモン、抗体を検出する診断や研究用途に広く使用されています。ELISAは高い感度、特異性、再現性を提供し、マイクロプレートとビーズベースの両方のフォーマットに適応できる利便性があります。Radio免疫測定法は、生物学的サンプル中の標的分子を検出するために放射性同位元素を使用する確立された技術です。非放射性技術の出現により、その人気は低下しているもの、RIAは、低濃度ホルモンの測定、薬剤モニタリング、受容体結合研究の評価など、特定のニッチ・アプリケーションにおいて依然として関連性を保っています。迅速診断検査は、血液や尿などの検体から、専門的な検査機器や人員を必要とせずに迅速な結果を得ることができるポイント・オブ・ケア検査機器です。これらの検査は、資源が限られた環境における感染症、妊娠、薬物乱用スクリーニングの診断に不可欠なツールとなっています。

検体非侵襲的な採取方法による唾液診断の出現

免疫測定法検体の選択は、対象とする疾患の種類、バイオマーカーの入手可能性、検体採取の容易さ、患者の快適さなどの要因によって決まる。血液は個人の健康状態を包括的に知ることができるため、免疫測定法の検体として好まれることが多いです。血液は、感染症、がんバイオマーカー、ホルモン値、自己免疫疾患などの検出に日常的に使用されています。唾液は、非侵襲的な採取方法と保管・輸送の容易さから、血液に代わる検体として普及しており、特にホルモンレベルの検出、薬物乱用検査、口腔病原体の同定、口腔全体の健康状態の評価に有用です。尿もまた、非侵襲的な採取方法と、乱用薬物、妊娠ホルモン、腎機能マーカー、尿路感染指標などの幅広い分析物を検出する能力により、免疫測定法で広く使用されている検体の一種です。

適応症感染症領域におけるニーズの高まりに対応するための免疫測定法テクノロジーにおける最適化

循環器内科は、世界的に心血管疾患（CVD）の有病率が高いことから、免疫測定法市場の主要セグメントとなっています。世界保健機関（WHO）によると、心血管疾患による死亡者数は年間約1,790万人で、世界的に見ても主要な死亡原因となっています。免疫測定法は、心筋梗塞、心不全、その他の関連疾患など、様々な心臓疾患の診断やモニタリングにおいて重要な役割を果たしています。特に、トロポニンなどのバイオマーカーは、胸痛や心筋虚血を示唆するその他の症状を呈する患者の急性冠症候群を評価するために不可欠です。糖尿病、甲状腺機能障害、ホルモンバランスの乱れなどの内分泌疾患は、世界的にますます増加しています。免疫測定法は、患者の検体中のホルモンレベルを正確に定量することで、この需要に応えています。免疫測定法市場において、感染症はもう一つの重要な分野です。細菌、ウイルス、真菌感染に対する懸念が世界的に広がっているからです。COVID-19のパンデミックは、感染症の特定と蔓延を監視するための迅速で正確な診断ツールの重要性をさらに浮き彫りにしました。免疫測定法は、特定の病原体や、感染に反応して免疫系が産生する抗体を検出し、タイムリーな介入や封じ込め対策を可能にする貴重なものです。腫瘍学では、免疫測定法はがんのスクリーニング、診断、治療効果のモニタリングに不可欠なものとなっています。免疫測定法は、カルサイノエンブリオニック抗原（CEA）や前立腺特異抗原（PSA）などの腫瘍バイオマーカーを検出し、様々な悪性腫瘍の早期発見、病期分類、予後評価において臨床医を支援し、患者に合わせた治療戦略を導きます。整形外科分野では、免疫測定法はプロコラーゲンタイプi N末端プロペプチド（PINP）やC末端架橋テロペプチド（CTX）のような骨代謝マーカーのモニタリングに使用され、骨粗鬆症やその他の骨関連疾患の診断に役立ちます。

エンドユーザー：救急医療、集中治療室、外来診療所における免疫測定法の需要増加

輸血や血液製剤の必要性から、血液銀行は免疫測定法市場において重要な役割を果たしています。免疫測定法は、ドナー血液サンプルのHIV、B型肝炎、C型肝炎、梅毒などの感染症のスクリーニングに使用されます。これらの検査で得られた結果は、輸血目的で使用される前の血液供給の安全性を確保するのに役立ちます。診断検査室では、免疫測定法を用いて日常的な医療検査を行い、生物学的サンプルに存在するさまざまなバイオマーカーを検出します。がん、糖尿病、心血管疾患、その他の慢性疾患などの早期診断に役立っています。飲食品業界では、食品中のアレルゲンや、原材料や最終製品に含まれる農薬や毒素などの汚染物質の検査に免疫測定法が必要とされています。飲食品は、規制要件を満たし、消費者の安全を確保するために、検出限界の低い信頼性の高い方法を求めています。病院は、救急医療、集中治療室、外来診療所など、複数の部門にわたって診断目的でこれらのアッセイを広範に使用しているため、免疫測定法市場の重要なエンドユーザー・セグメントの一つを構成しています。免疫測定法は、患者の様々な疾患や状態の迅速な診断とモニタリングを支援し、ヘルスケア専門家が患者の治療計画に関して十分な情報に基づいた意思決定を行うことを可能にします。製薬会社や医薬品開発業務受託機関（CRO）は、創薬、研究開発、臨床試験の段階で免疫測定法を利用しています。一方、研究・学術ラボでは、シグナル伝達経路、タンパク質間相互作用を含む基礎研究や、ワクチン開発、疾病監視プログラムなどの応用研究プロジェクトに特化した免疫測定法を必要としています。

地域別インサイト

米国とカナダでは、がんや心血管疾患などの慢性疾患の有病率が上昇しているため、免疫測定法の需要が拡大しています。これらの国々におけるヘルスケア支出の増加は、疾病の早期発見への注目の高まりも補足しています。検査室は、酵素結合免疫吸着測定法（ELISA）や化学発光測定法（CLIA）などの先端技術に多額の投資を行っています。これらとは別に、この地域で最近出願された特許は、交差反応性の問題を軽減しながら、アッセイの感度と特異性の改善を包含しています。EU諸国では、中東・アフリカ地域が、消費者の健康意識の高まりにより免疫測定法市場で大きな成長を遂げています。政府やヘルスケア機関が主導するイニシアチブにより、診断サービスへの公共投資が強化されています。新興国市場の主なプレーヤーは、地域特有の顧客ニーズに対応した新製品の開発に注力しています。インドや中国などのアジア太平洋地域の新興国は、医療費の増加、診断検査サービスを必要とする慢性疾患の有病率の上昇、検査室のインフラ整備、疾患の早期発見に対する意識の高まりなどから、免疫測定法メーカーにとって大きな成長機会をもたらしています。さらに、新興市場における特定の疾病パターンに対応するための製品のカスタマイズは、主要プロファイルの拡大に役立っています。さらに、地域政府は、革新的な診断法の開発における官民パートナーシップを促進するためのイニシアチブをいくつか立ち上げ、学術機関や民間企業に支援と投資を提供しています。

FPNVポジショニング・マトリックス

FPNVポジショニング・マトリックスは免疫測定法市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、免疫測定法市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.免疫測定法市場の市場規模および予測は？

2.免疫測定法市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.免疫測定法市場の技術動向と規制枠組みは？

4.免疫測定法市場における主要ベンダーの市場シェアは？

5.免疫測定法市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患と感染症の増加と早期診断の利点
    • 飲食品業界で免疫測定法の使用が増加
    • 医薬品開発におけるマルチプレックス検出技術の新たな応用
  • 抑制要因
    • 免疫測定法に関連する交差反応の問題
  • 機会
    • 免疫測定法に関連する自動化機器および装置の数の技術的進歩
    • 環境モニタリングにおける免疫測定法の高い可能性
  • 課題
    • サンプルの品質と試薬の性能のばらつきによるアッセイ検証の問題
• 市場セグメンテーション分析
  • 製品：感染症および自己免疫疾患の診断のための新しい免疫測定法キットの開発
  • 技術：食物アレルギーおよび乱用薬物治療における酵素結合免疫吸着測定技術の活用
  • 検体：非侵襲的な採取方法による唾液診断の出現
  • 適応症：感染症全般にわたる高まるニーズに応えるため、免疫測定法テクノロジー内で最適化を行う
  • エンドユーザー：救急医療、集中治療室、外来診療所全体で免疫測定法の需要が高まっています
• 市場動向分析
  • 南北アメリカにおける免疫測定の拡大を目的とした政府の資金援助による新しい持続可能な免疫測定のイントロダクション
  • アジア太平洋地域における感染症および自己免疫疾患の蔓延と効率的なヘルスケアソリューションの必要性の高まり
  • 免疫測定法の採用拡大に対する政府の支援が強化され、EMEA地域ではヘルスケア企業が存在感を強めている
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 免疫測定法市場：製品別

• アナライザ
• 消耗品

第7章 免疫測定法市場：技術別

• 化学発光免疫測定法
• 酵素免疫測定法
• 蛍光免疫測定法
• 放射免疫測定
• 迅速診断検査（RDT）/ラテラルフロー免疫測定法

第8章 免疫測定法市場標本別

• 血
• 唾液
• 尿

第9章 免疫測定法市場適応症別

• 心臓病学
• 内分泌学
• 感染症
• 腫瘍学
• 整形外科

第10章 免疫測定法市場：エンドユーザー別

• 血液銀行
• 診断研究所
• 飲食品会社
• 病院
• 製薬会社とCRO
• 調査・学術研究所

第11章 南北アメリカの免疫測定法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の免疫測定法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの免疫測定法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • サーモフィッシャーがオリンクを31億米ドルで買収、プロテオミクスのプレゼンスを拡大
  • 富士レビオとシスメックス、独自の免疫測定法の開発で提携
  • マインドレイ、ドイツに拠点を置くディアシス・ダイアグノスティック・システムズ社の株式75%を取得することに合意
  • CVCファンド「Shimadzu Future Innovation Fund」が免疫測定法技術を開発するIMMUNOSENS株式会社に出資しました。
  • Faponが新しい化学発光システムを導入
  • アッセイ開発感度が向上したベックマン・コールターのDxI 9000免疫測定法分析装置が2023 AACCで北米初公開
  • ベックマン・コールターと富士レビオが提携し、患者に優しい血液ベースのアルツハイマー病検査へのアクセスを強化
  • マカティメッド、フィリピンおよびASEAN初の病院としてアテリカ VTLi患者側免疫測定法アナライザーを買収
  • QuidelOrtho、Sofia 2 SARS Antigen+FIAのDe Novo FDA認可を取得
  • SGS、ポワティエ研究所で強化された自動免疫測定法テストを提供
  • シーメンス、免疫測定法計測器研究開発のためのセンター・オブ・エクセレンスを設立

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. IMMUNOASSAY MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOASSAY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. IMMUNOASSAY MARKET DYNAMICS
• FIGURE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOASSAY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 105. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 106. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 107. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 108. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 109. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 110. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 111. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 112. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 113. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 114. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 115. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 116. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 169. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 170. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 171. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 172. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 173. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 174. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 175. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 176. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 177. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 178. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 179. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 180. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 181. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 184. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 185. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 186. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 187. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 188. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 189. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 190. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 191. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 192. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 203. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 204. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 215. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 216. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 227. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 228. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 239. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 240. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 251. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 252. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 275. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 276. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 287. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 288. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 299. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 300. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 313. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 314. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 325. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 326. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 335. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 336. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 337. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 338. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 343. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 344. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 345. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 346. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 347. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 348. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 349. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 350. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 351. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 352. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 353. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 354. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 355. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 356. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 357. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 358. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 359. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 360. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 361. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 362. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 363. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 364. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 365. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 366. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 367. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 368. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 369. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 370. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 371. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 372. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 373. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 374. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 375. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 376. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 377. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 378. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 379. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 380. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 381. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
• TABLE 382. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
• TABLE 383. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 384. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 385. ISRAEL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 386. ISRAEL IMMUNOASSAY

[194 Pages Report] The Immunoassay Market size was estimated at USD 26.30 billion in 2023 and expected to reach USD 28.29 billion in 2024, at a CAGR 7.24% to reach USD 42.90 billion by 2030.

An immunoassay is a highly sensitive and specific biochemical technique used to quantify or detect a wide range of molecules, including proteins, hormones, antibodies, and other biologically relevant substances. The growth of the immunoassay market can be attributed to several influencing factors, such as the increasing prevalence of chronic diseases, rising demand for personalized medicine, expanding use of immunoassays in oncology diagnostics, and advancements in technology leading to higher throughput capabilities with improved accuracy. Moreover, the COVID-19 pandemic has also contributed significantly to the growth of this market due to the surge in demand for rapid testing solutions. However, high costs associated with advanced immunoassay systems may hamper their adoption by smaller laboratories or resource-limited settings. Additionally, stringent regulatory guidelines regarding product approvals can prolong the time to market for new products. To overcome these challenges and sustain business growth in the immunoassay market, organizations are exploring potential areas of innovation and research, including focusing on R&D efforts to create cost-effective solutions that cater to a wider user base across different healthcare settings worldwide. Additionally, collaborating with academic institutions and research centers to foster breakthrough innovations in assay design, targeting novel analytes or applications not currently addressed by existing products. Along with these, market participants are developing novel biomarkers for the early detection of diseases, leading to an expansion in clinical applications of immunoassays.

Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases

Analyzers are at the core of immunoassays as they facilitate the detection and measurement of target analytes in samples. These analyzers are typically used in clinical laboratories, hospitals, pharmaceutical companies, and research institutions to screen for various biomarkers and detect specific analytes such as hormones, proteins, and pathogens. There has been a growing need for analyzers with rapid turnaround times (TAT), high-throughput capabilities, and user-friendly interfaces. In response to these needs, manufacturers have introduced innovations such as chemiluminescence-based detection systems, multiplexed assays, and advanced software solutions to improve efficiency and provide accurate results.

Consumables play a critical role in immunoassays by ensuring reliable test results through high-quality reagents, kits, and other disposable items. In consumables, reagents play an essential role in performing immunoassays by facilitating specific binding interactions between antibodies and antigens. These include primary and secondary antibodies, enzyme-labeled conjugates, substrates, buffers, and other necessary chemicals. The performance characteristics of these reagents directly affect assay reliability and reproducibility. Immunoassay kits consist of a complete set of pre-packaged reagents, along with detailed protocols for conducting specific assays. Advantages such as ease of use, standardization, and optimized performance have increased demand for ready-to-use kits in laboratories worldwide. Microwell plates and tubes serve as support structures for various immunoassays, offering scalability and high-throughput capabilities by allowing multiple samples to be analyzed simultaneously. Their material composition plays a significant role in minimizing non-specific binding while maintaining optimal conditions for analyte detection.

Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment

The chemiluminescence immunoassay (CLIA) is a highly sensitive and specific technology that measures the concentration of an analyte through the emission of light from a chemical reaction. CLIA has gained popularity recently due to its high throughput, rapid results, and favorable signal-to-noise ratios, which are beneficial in detecting low-abundance biomarkers, infectious diseases, and hormone levels. Enzyme-linked fluorescence assays (ELFA) involve using enzyme-labeled antibodies and fluorescent substrates to quantify specific analytes. ELFA provides a rapid analysis with high sensitivity and specificity while requiring relatively small sample volumes. This technology finds utility in various applications such as infectious disease diagnosis, autoimmune disorders detection, and therapeutic drug monitoring. Enzyme-linked immunosorbent assays (ELISA) are widely used in diagnostics and research applications to detect proteins, peptides, hormones, and antibodies. ELISA offers high sensitivity, specificity, and reproducibility with the convenience of being adaptable to both microplate and bead-based formats. Radioimmunoassay is a well-established technique that uses radioisotopes to detect target molecules in biological samples. Despite its declining popularity due to the emergence of non-radioactive techniques, RIA still holds relevance in specific niche applications such as the measurement of low-concentration hormones, drug monitoring, and assessment of receptor binding studies. Rapid diagnostic tests are point-of-care testing devices offering quick results from a sample such as blood or urine without requiring specialized laboratory equipment or personnel. These tests have become vital tools in diagnosing infectious diseases, pregnancy, and drug abuse screening in resource-limited settings.

Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods

The choice of immunoassay specimen depends on factors such as the type of disease targeted, biomarker availability, ease of sample collection, and patient comfort. Blood is often the preferred specimen type for immunoassays due to its ability to provide comprehensive insights into an individual's health status. It is routinely used to detect infectious diseases, cancer biomarkers, hormone levels, and autoimmune disorders, among other applications. Saliva has emerged as a popular alternative to blood due to its non-invasive collection methods and ease of storage/transportation, which is particularly useful for detecting hormone levels, drug abuse testing, oral pathogens identification, and assessment of overall oral health status. Urine is another widely used specimen type in immunoassays due to its non-invasive collection procedure and ability to detect a wide range of analytes, such as drugs of abuse, pregnancy hormones, kidney function markers, and urinary tract infection indicators.

Indication: Optimization within immunoassay technologies to cater growing need across infectious disease

Cardiology is a major segment in the immunoassay market owing to the high prevalence of cardiovascular diseases (CVDs) worldwide. According to the World Health Organization, cardiovascular diseases account for approximately 17.9 million deaths annually, making it a major cause of mortality globally. Immunoassays play a critical role in diagnosing and monitoring various cardiac conditions such as myocardial infarction, heart failure, and other related disorders. In particular, biomarkers such as troponin are essential for evaluating acute coronary syndrome in patients presenting with chest pain or other symptoms suggestive of myocardial ischemia. Endocrine disorders like diabetes, thyroid dysfunction, and hormonal imbalances are increasingly affecting global populations. Immunoassays cater to this demand by accurately quantifying hormone levels in patients' samples. Infectious Disease represents another significant area within the immunoassay market due to widespread concerns over bacterial, viral, and fungal infections worldwide. The COVID-19 pandemic has further highlighted the importance of rapid and accurate diagnostic tools to identify and monitor the spread of infectious diseases. Immunoassays are valuable in detecting specific pathogens or antibodies produced by the immune system in response to infection, enabling timely intervention and containment measures. In Oncology, immunoassays have become indispensable for cancer screening, diagnosis, and monitoring treatment effectiveness. Immunoassays detect tumor biomarkers such as carcinoembryonic antigen (CEA) or prostate-specific antigen (PSA) that can aid clinicians in early detection, staging, and prognostic evaluation of various malignancies and guiding personalized therapeutic strategies for patients. In the field of orthopedics, immunoassays are used to monitor bone metabolism markers like procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide (CTX), which assist in diagnosing osteoporosis and other bone-related disorders.

End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics

Blood banks play a critical role in the immunoassay market due to the need for blood transfusions and blood-based products. Immunoassays are employed to screen for infectious diseases such as HIV, Hepatitis B and C, and syphilis in donor blood samples. The results obtained from these tests help ensure the safety of blood supplies before they are used for transfusion purposes. Diagnostic laboratories perform routine medical tests using immunoassays to detect different biomarkers present in biological samples. Across laboratories, assays aid in early diagnostics of diseases such as cancer, diabetes, cardiovascular disorders, and other chronic conditions. The food & beverage industry requires immunoassays for testing allergens in food products and contaminants, including pesticides and toxins in raw materials or finished goods. Food & beverage seek reliable methods with low detection limits to meet regulatory requirements and ensure consumer safety. Hospitals constitute one of the significant end-user segments of the immunoassay market due to their extensive use of these assays for diagnostic purposes across multiple departments, such as emergency care, intensive care units, and outpatient clinics. Immunoassays aid in the rapid diagnosis and monitoring of various diseases and conditions in patients, enabling healthcare professionals to make informed decisions regarding patient treatment plans. Pharmaceutical companies and contract research organizations (CROs) rely on immunoassays for drug discovery, development, and clinical trial phases. Whereas research & academic labs often need specialized immunoassays for basic research studies involving signaling pathways, protein-protein interactions, and applied research projects such as vaccine development and disease surveillance programs.

Regional Insights

In the Americas, the United States and Canada have witnessed a growing demand for immunoassays due to a rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Increasing healthcare spending in these countries has also supplemented increased focus on early detection of diseases; laboratories are investing heavily in advanced technologies such as enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassays (CLIA). Apart from these, recent patents filed in this region encompass improvements in assay sensitivity and specificity while reducing cross-reactivity issues. In EU countries, the Middle East and Africa region has seen significant growth in the immunoassay market due to rising consumer health awareness. Initiatives led by governments and healthcare organizations have bolstered public investment in diagnostic services. Key players in this market focus on developing new products catering to specific regional customer requirements. Emerging countries across the Asia Pacific, such as India and China, present a considerable growth opportunity for immunoassay manufacturers due to increasing healthcare expenditure, rising prevalence of chronic diseases requiring diagnostic testing services, improving laboratory infrastructure, and growing awareness about early disease detection. Furthermore, customizing products to cater to specific disease patterns in emerging markets has helped expand key profiles. Additionally, the regional government has launched several initiatives to promote public-private partnerships in developing innovative diagnostic methods, providing support and investment for academic institutions and private enterprises.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immunoassay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immunoassay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immunoassay Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Almac Group Limited, ANP Technologies, Inc., Autobio Diagnostics Co., Ltd., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioLegend, Inc., bioMerieux S.A., Biosurfit SA, Boditech Med Inc., Charles River Laboratories International, Inc., Danaher Corporation, Diasorin S.p.A., Dynex Technologies, Inc., Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Gyros Protein Technologies AB, H.U. Group Holdings Inc., J. Mitra & Co. Pvt. Ltd., Kamiya Biomedical Company, Koninklijke Philips N.V., Merck KGaA, MiCo BioMed, Inc., NanoEntek, Nanomix, Inc., OPKO Health, Inc., PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Quanterix Corporation, QuidelOrtho Corporation, Randox Laboratories Ltd., Shenzhen Micropoint Biotechnologies Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Sysmex Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Tosoh Corporation, WAK-Chemie Medical GmbH, Zoetis Inc., and Zybio Inc..

Market Segmentation & Coverage

This research report categorizes the Immunoassay Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Analyzer
  • Consumables
    • Assay Kits
    • Microwell Plates & Tubes
    • Reagents
• Technology
  • Chemiluminescence Immunoassay
  • Enzyme-linked Immunosorbent Assay
  • Fluoroimmunoassay
  • Radioimmunoassay
  • Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay

• Specimen
  • Blood
  • Saliva
  • Urine

• Indication
  • Cardiology
  • Endocrinology
  • Infectious Disease
  • Oncology
  • Orthopedics

• End User
  • Blood Banks
  • Diagnostics Laboratories
  • Food & Beverage Companies
  • Hospitals
  • Pharmaceutical Companies & CROs
  • Research & Academic Laboratories

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immunoassay Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immunoassay Market?

3. What are the technology trends and regulatory frameworks in the Immunoassay Market?

4. What is the market share of the leading vendors in the Immunoassay Market?

5. Which modes and strategic moves are suitable for entering the Immunoassay Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising chronic and infectious diseases and benefits of early diagnosis
    • 5.1.1.2. Growing usage of immunoassay in the food & beverage sector
    • 5.1.1.3. Emerging application of multiplex detection immunoassay technique in drug development
  • 5.1.2. Restraints
    • 5.1.2.1. Cross-reactivity issues associated with immunoassay
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the number of automated instruments and equipment associated with immunoassay
    • 5.1.3.2. High potential of immunoassay in environment monitoring
  • 5.1.4. Challenges
    • 5.1.4.1. Issues with assay validation due to variations in sample quality and reagent performance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases
  • 5.2.2. Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment
  • 5.2.3. Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods
  • 5.2.4. Indication: Optimization within immunoassay technologies to cater growing need across infectious disease
  • 5.2.5. End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics
• 5.3. Market Trend Analysis
  • 5.3.1. Introduction of novel sustainable immunoassays with government funding to scale up of immunoassays in the Americas
  • 5.3.2. Prevalence of infectious and autoimmune diseases, and rising need for efficient healthcare solution in the Asia-Pacific region
  • 5.3.3. Increasing support by government to expand adoption of immunoassay coupled with strong presence of healthcare companies in EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Immunoassay Market, by Product

• 6.1. Introduction
• 6.2. Analyzer
• 6.3. Consumables

7. Immunoassay Market, by Technology

• 7.1. Introduction
• 7.2. Chemiluminescence Immunoassay
• 7.3. Enzyme-linked Immunosorbent Assay
• 7.4. Fluoroimmunoassay
• 7.5. Radioimmunoassay
• 7.6. Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay

8. Immunoassay Market, by Specimen

• 8.1. Introduction
• 8.2. Blood
• 8.3. Saliva
• 8.4. Urine

9. Immunoassay Market, by Indication

• 9.1. Introduction
• 9.2. Cardiology
• 9.3. Endocrinology
• 9.4. Infectious Disease
• 9.5. Oncology
• 9.6. Orthopedics

10. Immunoassay Market, by End User

• 10.1. Introduction
• 10.2. Blood Banks
• 10.3. Diagnostics Laboratories
• 10.4. Food & Beverage Companies
• 10.5. Hospitals
• 10.6. Pharmaceutical Companies & CROs
• 10.7. Research & Academic Laboratories

11. Americas Immunoassay Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Immunoassay Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Immunoassay Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Thermo Fisher to Acquire Olink for USD 3.1 billion, Expanding Proteomics Presence
  • 14.3.2. Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays
  • 14.3.3. Mindray Has Agreed to Acquire 75% Stake in Germany-Based DiaSys Diagnostic Systems GmbH
  • 14.3.4. CVC Fund "Shimadzu Future Innovation Fund" has Invested in IMMUNOSENS Co., Ltd., Developing Immunoassay Technology.
  • 14.3.5. Fapon Rolls Out New Chemiluminescence Immunoassay System
  • 14.3.6. Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
  • 14.3.7. Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
  • 14.3.8. MakatiMed First PH and ASEAN Hospital to Acquire Atellica VTLi Patient-Side Immunoassay Analyzer
  • 14.3.9. QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA
  • 14.3.10. SGS Offers Enhanced Automated Immunoassay Testing at Poitiers Laboratory
  • 14.3.11. Siemens launches Centre of Excellence for Immunoassay Instrument R&D

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio